QIAGEN Strengthens QIAstat-Dx With New Barcelona Site

Drive Growth in Infectious Diseases and Precision Medicine Testing

02-Dec-2024 - QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to move its QIAstat-Dx operations within the Barcelona area to a new site in Esplugues de Llobregat as part of a multi-year investment to strengthen this business. Set to open in early 2026, the new site will cover the ...

QIAGEN fully acquires NeuMoDx Molecular

QIAGEN acquires remaining 80.1% stake in NeuMoDx Molecular, Inc. for $248 million

18-Sep-2020 - QIAGEN N.V. announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology. The transaction was completed after ...

QIAGEN dramatically ramping up global production capacity for RNA extraction kits for use in detection of SARS-CoV-2 coronavirus

18-Mar-2020 - QIAGEN announced plans to dramatically ramp up global production capacity of RNA extraction kits that are used as part of workflows around the world to detect nucleic acid from SARS-CoV-2, the novel coronavirus that causes COVID-19. QIAGEN has historically allocated global production capacity to ...

QIAGEN acquires Spanish diagnostics start-up company

QIAGEN enters into agreement to acquire STAT-Dx

09-Feb-2018 - QIAGEN N.V. announced it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven ...

QIAGEN and CENTOGENE to collaborate in bioinformatics for genetic diseases

Aiding the analysis of hereditary disorders by integrating genomic and clinical databases

11-Oct-2017 - QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG announced a collaboration and co-marketing agreement to provide customers more complete Sample to Insight research and clinical testing solutions in rare genetic diseases. CENTOGENE is a leading rare disease company providing ...

Bristol-Myers Squibb and QIAGEN collaborate

Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies

07-Jun-2017 - Bristol-Myers Squibb Company and QIAGEN have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in cancer ...

QIAGEN and Biotype Diagnostics form partnership

30-Jun-2015 - QIAGEN and Biotype Diagnostics GmbH announced that they have entered into a partnership to establish Biotype Innovation GmbH ("Biotype Innovation"). The new company will develop and commercialize molecular diagnostic workflows initially for personalized healthcare applications based on QIAGEN’s ...

QIAGEN adds promising genomic biomarkers to pipeline

Mutations of SF3B1 gene indicate favorable prognosis for patients with bone marrow disorders

30-Jul-2014 - QIAGEN N.V. announced it has acquired an exclusive global license to the biomarker SF3B1 from the University of Tokyo. SF3B1 is believed to play a critical role in the prognosis of patients with myelodysplastic syndromes (MDS), a group of hematological cancers in which bone marrow does not ...

QIAGEN announces third co-development program for companion diagnostics paired with Lilly’s investigational cancer compounds

21-Nov-2013 - QIAGEN announced an agreement with Eli Lilly and Company to develop and commercialize a molecular companion diagnostic paired with a novel Lilly oncology compound. This is the third co-development project by QIAGEN and Lilly to create companion diagnostics, which are tests that analyze genomic ...

QIAGEN and Bayer HealthCare partner to develop companion diagnostics to guide treatment decisions for targeted cancer therapies

26-Oct-2012 - QIAGEN and Bayer HealthCare announced a collaboration agreement for the development and commercialization of companion diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment of various solid tumors. Companion diagnostics are tests that unlock molecular ...